TY - JOUR
T1 - Management of patients with persistent or recurrent Cushing’s disease after initial pituitary surgery
AU - Capatina, Cristina
AU - Hinojosa-Amaya, José Miguel
AU - Poiana, Catalina
AU - Fleseriu, Maria
N1 - Funding Information:
The authors wish to acknowledge editorial assistance received from Shirley McCartney, PhD, of Oregon Health & Science University.
Publisher Copyright:
© 2020 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2020/9/2
Y1 - 2020/9/2
N2 - Introduction: Treatment options for persistent and recurrent Cushing’s disease (CD) include an individualized approach for repeat surgery, medical treatment, radiation therapy (RT), and bilateral adrenalectomy (BLA). Areas covered: In this expert opinion perspective, the authors review the latest treatment(s) for persistent/recurrent CD. A PubMed search was undertaken (English articles through May 2020) and relevant articles discussed. Repeat pituitary surgery should be considered in most patients with proven hypercortisolism; there is potential for cure with low risk of major complications. Medical therapy is valuable either alone, while awaiting the effects of RT, or in preparation for BLA. Medical therapy includes steroidogenesis inhibitors, agents that act at the pituitary or glucocorticoid receptor level, and novel agents in development. Radiation therapy has been used successfully to treat CD, but hypopituitarism risk and delayed efficacy (improved with radiosurgery) are major drawbacks. Laparoscopic BLA is safe and effective in patients with severe, difficult-to-manage hypercortisolism, but long-term follow-up is required as corticotroph tumor progression can develop. Expert opinion: Treatment of persistent/recurrent CD is challenging. Most patients require >1 therapy to achieve long-lasting remission. There is currently no ideal single treatment option that provides high and rapid efficacy, low adverse effects, and preserves normal pituitary-adrenal axis function.
AB - Introduction: Treatment options for persistent and recurrent Cushing’s disease (CD) include an individualized approach for repeat surgery, medical treatment, radiation therapy (RT), and bilateral adrenalectomy (BLA). Areas covered: In this expert opinion perspective, the authors review the latest treatment(s) for persistent/recurrent CD. A PubMed search was undertaken (English articles through May 2020) and relevant articles discussed. Repeat pituitary surgery should be considered in most patients with proven hypercortisolism; there is potential for cure with low risk of major complications. Medical therapy is valuable either alone, while awaiting the effects of RT, or in preparation for BLA. Medical therapy includes steroidogenesis inhibitors, agents that act at the pituitary or glucocorticoid receptor level, and novel agents in development. Radiation therapy has been used successfully to treat CD, but hypopituitarism risk and delayed efficacy (improved with radiosurgery) are major drawbacks. Laparoscopic BLA is safe and effective in patients with severe, difficult-to-manage hypercortisolism, but long-term follow-up is required as corticotroph tumor progression can develop. Expert opinion: Treatment of persistent/recurrent CD is challenging. Most patients require >1 therapy to achieve long-lasting remission. There is currently no ideal single treatment option that provides high and rapid efficacy, low adverse effects, and preserves normal pituitary-adrenal axis function.
KW - Cushing’s disease
KW - adrenalectomy
KW - medical therapy
KW - persistence
KW - radiotherapy
KW - recurrence
KW - repeat surgery
UR - http://www.scopus.com/inward/record.url?scp=85089681973&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089681973&partnerID=8YFLogxK
U2 - 10.1080/17446651.2020.1802243
DO - 10.1080/17446651.2020.1802243
M3 - Review article
C2 - 32813595
AN - SCOPUS:85089681973
SN - 1744-6651
VL - 15
SP - 321
EP - 339
JO - Expert Review of Endocrinology and Metabolism
JF - Expert Review of Endocrinology and Metabolism
IS - 5
ER -